Browsing by Author Vranckx, Pascal

فهرست الفبایی 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
آ ب پ ت ث ج چ ح خ د ذ ر ز ژ س ش ص ض ط ظ ع غ ف ق ک گ ل م ن و ه ی
 
Showing results 1 to 10 of 10
PreviewIssue DateTitleAuthor(s)
2018 EHJ Volume 39 Issue 2 January (14).pdf.jpg20182017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST -segment elevation The Task Force for the management of acute myocardial infarctionUk, Chiara Bucciarelli-ducci; Germany, Gerhard Hindricks; Germany, Adnan Kastrati; Lenzen, Mattie J; Denmark, Eva Prescott; Vranckx, Pascal
2018 AHJ Volume 196 February (12).pdf.jpg2018Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention ( PCI ) with stent placement : Rationale and design of the ENTRUST-AF PCI trialVranckx, Pascal; Valgimigli, Marco; Tijssen, G; Reimitz, Paul-egbert; Eckardt, Lars
2018 Lancet Volume 392 Issue 10150 September (7).pdf.jpg2018Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trialValgimigli, Marco; Frigoli, Enrico; Leonardi, Sergio; Vranckx, Pascal; Rothenbühler, Martina; Tebaldi, Matteo; Varbella, Ferdinando; Calabrò, Paolo; Garducci, Stefano; Rubartelli, Paolo; Briguori, Carlo; Andó, Giuseppe; Ferrario, Maurizio; Limbruno, Ugo; Garbo, Roberto
medicine article k (312).pdf.jpg2013Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: Rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint steValgimigli, Marco; Patialiakas, Athanasios; Thury, Attila; Colangelo, Salvatore; Campo, Gianluca; Tebaldi, Matteo; Ungi, Imre; Tondi, Stefano; Roffi, Marco; Menozzi, Alberto; De Cesare, Nicoletta; Garbo, Roberto; Meliga, Emanuele; Testa, Luca; Gabriel, Henrique M.; Airoldi, Flavio; Ferlini, Marco; Liistro, Francesco; Dellavalle, Antonio; Vranckx, Pascal; Briguori, Carlo
2016 AHJ Volume 175 May (10).pdf.jpg2016Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease , non – ST-segment elevation acute coronary syndrome , and ST-segment elevation myocardial infarctionPilgrim, Thomas; Vranckx, Pascal; Valgimigli, Marco; Stefanini, Giulio G
2018 Circulation Volume 137 Issue 24 June (10).pdf.jpg2018Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus DocumentGarcia-Garcia, Hector M.; McFadden, Eugène P.; Farb, Andrew; Mehran, Roxana; Stone, Gregg W.; Spertus, John; Onuma, Yoshinobu; Morel, Marie-angèle; van Es, Gerrit-Anne; Zuckerman, Bram; Fearon, William F.; Taggart, David; Kappetein, Arie-Pieter; Krucoff, Mitchell W.; Vranckx, Pascal; Windecker, Stephan; Cutlip, Donald; Serruys, Patrick W.
2018 EHJ Volume 39 Issue 23 June (15).pdf.jpg2018Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus DocumentGarcia-Garcia, Hector M.; McFadden, Eugène P.; Farb, Andrew; Mehran, Roxana; Stone, Gregg W.; Spertus, John; Onuma, Yoshinobu; Morel, Marie-angèle; van Es, Gerrit-Anne; Zuckerman, Bram; Fearon, William F.; Taggart, David; Kappetein, Arie-Pieter; Krucoff, Mitchell W.; Vranckx, Pascal; Windecker, Stephan; Cutlip, Donald; Serruys, Patrick W.
2018 Lancet Volume 392 Issue 10151 September (15).pdf.jpg2018Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-laVranckx, Pascal; Valgimigli, Marco; Jüni, Peter; Hamm, Christian; Steg, Philippe Gabriel; Heg, Dik; van Es, Gerrit Anne; McFadden, Eugene P; Onuma, Yoshinobu; van Meijeren, Cokky; Chichareon, Ply; Benit, Edouard; Möllmann, Helge; Janssens, Luc; Ferrario, Maurizio; Mosch
2017 AHJ Volume 184 February (3).pdf.jpg2017Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO studyWindecker, Stephan; Tijssen, Jan; Giustino, Gennaro; Guimar??es, Ana H C; Mehran, Roxana; Valgimigli, Marco; Vranckx, Pascal; Welsh, Robert C.; Baber, Usman; van Es, Gerrit Anne; Wildgoose, Peter; Volkl, Albert a.; Zazula, Ana; Thomitzek, Karen; Hemmrich, Melanie; Danga
2017 AHJ Volume 190 August (12).pdf.jpg2017Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortiumSeltzer, Jonathan H.; Heise, Ted; Carson, Peter; Canos, Daniel; Hiatt, Jo Carol; Vranckx, Pascal; Christen, Thomas; Cutlip, Donald E.